SpineGuard Looks to Break Even by 2018, Names Co-Founder CEO Post author:Sam Post published:July 6, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Data To Be Presented At Highlighting GENFIT???s Latest Progress In NASH Biomarker Diagnostics, Identifying Novel Compounds With Potent Antifibrotic Properties, And Illustrating The Opportunities In Anti-NASH Drug Combinations April 4, 2017 AbbVie’s Elagolix Dazzles in Phase III Trial March 12, 2018 CRISPR, Editas Medicine and Intellia Fall as Scientific Paper Warns of Unintended Mutations Linked to Gene-Editing May 30, 2017
Data To Be Presented At Highlighting GENFIT???s Latest Progress In NASH Biomarker Diagnostics, Identifying Novel Compounds With Potent Antifibrotic Properties, And Illustrating The Opportunities In Anti-NASH Drug Combinations April 4, 2017
CRISPR, Editas Medicine and Intellia Fall as Scientific Paper Warns of Unintended Mutations Linked to Gene-Editing May 30, 2017